COVID-19Regulatory

Do countries with high rates of malaria have fewer coronavirus deaths?

April 8, 2020 / By Hollie McKay | Fox News

It has become one of the most controversial words in the world: hydroxychloroquine.

For several weeks, the primarily anti-malaria drug has been touted by President Trump and others in the media as a vital aid in treating those suffering from coronavirus, given that there is not yet a Food and Drug Administration-approved treatment.

So is there any possible correlation between countries where the drug is routinely administered due to high malaria rates and lower cases of COVID-19? It’s too early to tell, medical professionals say, but it’s part of the investigation process.

“If you look [at the] countries where malaria is more prevalent and countries where COVID-19 infections are prevalent, you will find a striking difference. This correlation needs to be explored further as this is not just a mere coincidence,” Dr. David Nazarian, a Beverly Hills-based physician, diplomate at the American Board of Internal Medicine and founder of My Concierge MD, told Fox News.

The drug initially burgeoned on the scene with an FDA thumbs-up in 1955 and has been used as a proven remedy in the treatment of malaria, rheumatoid arthritis and lupus.

After a very small preliminary study conducted in France in the early weeks of COVID-19, Trump and other physicians pinned it as an aid in preventing the virus’ cells from entering the body’s cells, thus possibly helping clear the infection sooner.

READ THE REST HERE

Print Friendly, PDF & Email
Tags

Chris J. Stewart

Chris currently serves as Chief Executive Officer of Surgio Health as well as COO at Ortho Spine Partners. Chris has close to 20 years of healthcare management experience with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that solve real problems that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help drive better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button
Close